Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes - Wikidata - awgldk - TriplyDB

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

http://www.wikidata.org/entity/Q28741419

about

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion Cardiovascular safety of anti-diabetic drugs A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond Adverse Effects of GLP-1 Receptor Agonists Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials Cardiovascular effects of incretin therapy in diabetes care.Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.Evolution of exenatide as a diabetes therapeutic.Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.GLP-1 based therapies: differential effects on fasting and postprandial glucose.Potential cardiovascular effects of incretin-based therapies.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.Update on incretin hormones.Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.Managing diabetes in patients with diabetes of long duration.Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.Managing diabetes in the middle-aged patient when loss of glycemic control occurs.A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.

P2860

Q26740171-2C2BC4F8-812D-4869-BC3A-EB4B6C2F2162 Q26741082-C388828B-39D9-4300-A7B0-6027F75A9892 Q26799389-A03D85E8-77E1-484F-BA9C-3E8BCED52479 Q26801346-066A6F16-84D4-4F64-BE8B-83D54304A512 Q26823085-50E0DE07-3DFB-415E-9AC0-7FE8F23E613C Q26852590-4007F3E7-8F62-43F6-8B2D-1E40FF7ED7E7 Q28078225-265B7C81-FFBC-4795-A6E1-D1276C5B8A3A Q30238791-CCEF9DC8-7DCD-4946-A96B-FBEAE8C57C96 Q30888375-DECE5AC6-7F39-4297-9BE7-400C32FF9E3F Q33801801-AF8080CD-D5EB-4FA2-A020-BC1CE24ADA12 Q34171759-830A0E41-9ED4-4845-ADB0-82121A289EF2 Q34771795-6B7CD17F-33DF-489A-9116-DC2A15930578 Q35017639-B958C445-38FD-4B9C-9D11-03C0B4E5C5F2 Q35249760-1BF7D1F4-9EF7-42F1-98B9-6A9D74A2ED83 Q35780935-141FDC03-21CC-4D09-9305-AE96D95E0B16 Q36023385-2F8721CE-FAAF-4DB5-89C3-528689558519 Q36209444-4CC4B91F-5A15-496C-AFC1-D29841A74609 Q36498624-954E9F22-FD20-47D9-AEA3-764912529308 Q36498695-FF97FCF8-FBF7-430E-90AB-D7B349AB2EB8 Q36584204-9C414088-1488-4F0E-86E4-0313B42E67F2 Q36611527-D3A862BB-C34D-4A0F-ABEE-0C935ACABFF5 Q36670931-F080E8A0-DD6D-4AAF-9217-B3BB3BEB4C28 Q36755470-738171E5-DE3F-4196-BE9C-DB4F57215A94 Q36877205-7C9087BC-F19F-4B58-9D89-630B9036AB21 Q37320537-C02D26D0-05D9-4738-B499-BDECF610DBB1 Q37562586-D71B9AC4-9869-4F90-B4BF-6EABEC3A3BD6 Q37696559-4C1C9B10-238D-4338-84E6-4E9FEFFAB89A Q37929511-D0209080-4306-4985-BAF8-035B03EEA2CC Q37974712-436BB78F-E1D5-400E-9B1A-3D5FD6A986A7 Q37990619-E0F7A045-3B4F-4871-99F1-76AA3D02C1CE Q37995760-A6C6D5B4-065D-4414-9D30-4341B4AC6543 Q38002008-173A5D7B-3FA1-4B7C-A88D-776DAC724A74 Q38006504-84FB86C6-D39F-4212-B49D-3802FF979282 Q38008596-4D74549F-8136-4BB1-AFF2-CDA53C656EC4 Q38015776-288B60B0-7403-42E9-AD27-2397397CDBD9 Q38016390-81187F0E-0CEA-4EA1-81AA-D9F37CE4A1BA Q38020016-F20813AD-74F9-4ABB-B070-A680D84F21C1 Q38020941-4BD32967-24CD-4DFA-A93B-04254F5AEF2A Q38036773-C989AB66-974E-4ADC-875B-4A24F1007D60 Q38046641-912CCF27-68DF-4EDB-8E01-50C554309EDE

P2860

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

http://www.wikidata.org/entity/Q28741419

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@ast

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@en

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@nl

type

label

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@ast

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@en

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@nl

prefLabel

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@ast

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@en

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@nl

P1433

Q28741419-5125CAE6-C9E5-43D4-93E0-86F3D41BCC8A

P1476

Q28741419-48A4742F-9A4D-4F95-9198-189C1931ED91

P2093

Q28741419-0836E61E-941E-4396-BECC-CAFA006AE0A4

Q28741419-8DD4B129-DF41-4CD8-9371-7DE08C002BFF

Q28741419-AAFB0BA8-1090-4610-AC4B-4EC01239FFF5

Q28741419-E90800F8-77B1-4B08-95F7-DA05BE0EBBD6

Q28741419-EECA3D8F-9DD0-4F4A-AAAC-DE5214E80B99

Q28741419-F7820DC4-4440-466F-B388-6E098F7453F9

P2860

Q28741419-02287C57-C36D-4AB5-A9B3-A74067137F1D

Q28741419-05482AED-0DF4-4794-B301-B8D900DD7C2F

Q28741419-064C6F17-B181-40C8-9672-3DE1C53FA013

Q28741419-095024F7-1F37-4097-9CAA-D79B67FF5B4E

Q28741419-0ABC7BA6-15EF-49C6-83D4-76C7AE48362A

Q28741419-0AD71F76-3C10-4E74-9443-74E4020D3E4B

Q28741419-0DDCE125-69AB-4C28-9D82-4E84B8F87293

Q28741419-0EE4E605-88F1-4835-86CE-C0F7125AE40B

Q28741419-0FB1F711-BEFC-494D-BB29-C8C3F74809C2

Q28741419-1B342171-2D31-4E1C-B94B-F1662573DC63

P2888

Q28741419-20E6DFDD-05B1-4305-BF9C-EF735771A920

P304

Q28741419-90366D4E-E776-4B38-90B9-B61DDD425776

P31

Q28741419-787d7b5a-0088-4905-8b98-13abfd0cd0aa

Q28741419-E6FEAE79-AAC6-4ECF-AA9A-6E5668E2FCCB

P3181

Q28741419-41D9FE25-1942-44AC-A1AF-13C294E53DC3

P356

Q28741419-01057C49-FBC0-4F93-8FFD-D9B11ED65834

P407

Q28741419-1A5D130B-6096-45C7-96B3-933F2A200D75

P433

Q28741419-41D3509C-C837-4B4D-8DE7-C6EEEC72DB19

P478

Q28741419-969A35F7-A314-45CD-A07E-3011E46352FB

P577

Q28741419-AC0C4CD5-6D36-4DBE-9D7C-0AC452493D11

P5875

Q28741419-563B2446-69F2-4078-AE98-0E9443C5AC0A

P6179

Q28741419-4CD95C90-D986-4ED3-AFF9-C1AFD68A400A

P698

Q28741419-DCFFA542-7898-4DB5-ADED-761DA85F9FE7

P921

Q28741419-379E3EDF-CB10-47C7-B098-A58682C70D69

Q28741419-D359C663-0AF8-4B03-87B2-F74DB015C5AF

P932

Q28741419-38E969EC-6A3C-4F00-8F5A-38E23B235EA0

P3181

P356

1475-2840-10-22

P1433

Cardiovascular Diabetology

P1476

Cardiovascular safety of exena ...... ticipants with type 2 diabetes

@en

P2093

Byron J Hoogwerf

http://www.w3.org/2001/XMLSchema#string

Dawn Nicewarner

http://www.w3.org/2001/XMLSchema#string

Irina Yushmanova

http://www.w3.org/2001/XMLSchema#string

Jenny Han

http://www.w3.org/2001/XMLSchema#string

Larry Shen

http://www.w3.org/2001/XMLSchema#string

Robert Ratner

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

P2888

1475-2840-10-22

P304

22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3363966

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1475-2840-10-22

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50408561

http://www.w3.org/2001/XMLSchema#string

P6179

1001057821

http://www.w3.org/2001/XMLSchema#string

P698

21410975

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

type-2 diabetes

P932

3070629

http://www.w3.org/2001/XMLSchema#string